{"id":22774,"date":"2015-11-12T08:32:31","date_gmt":"2015-11-12T07:32:31","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=22774"},"modified":"2015-11-12T11:34:28","modified_gmt":"2015-11-12T10:34:28","slug":"boehringer-investira-11-mld-in-rs-nei-prossimi-5-anni","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/boehringer-investira-11-mld-in-rs-nei-prossimi-5-anni\/","title":{"rendered":"Boehringer will invest 11 billion in R&amp;D over the next 5 years"},"content":{"rendered":"<p><img decoding=\"async\" class=\"alignleft\" src=\"http:\/\/www.iralab.it\/img\/ricerca_sviluppo_ita.jpg\" alt=\"\" \/>Boehringer Ingelheim announces new R&amp;D strategy and five-year investment plan. Over the next 5 years, the company is committed to investing a total of 11 billion euros in its new R&amp;D program, of which 5 billion in preclinical and 1.5 billion in collaborations with external partners. The company aims to develop next-generation therapies and maintain its competitive position.<\/p>\n<p>The new R&amp;D strategy embraces so-called &#039;open innovation&#039; with external collaborations that best combine the capabilities and experience of Boehringer Ingelheim and research in new emerging fields for the discovery of new drugs.<\/p>\n<p>\u201cThe 11 new launches in 2014 and 2015 testify to the extraordinary capacity of Boehringer Ingelheim&#039;s internal Research &amp; Development \u2013 comments Andreas Barner, Chairman of the Board of Boehringer Ingelheim \u2013 the new strategy and the new program reflect our long-term, focused to sustainable growth and will enable us to continue our long and successful tradition of delivering therapeutic innovations of great value to patients.\u201d<\/p>\n<p>(<a href=\"http:\/\/streamer.adnkronos.com\/Salute\/Newsletter\/data\/Pk180e15.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">BDC \u2013 November 12, 2015 Pharma<em>Kronos<\/em><\/span><\/a>)<\/p>\n<p>Related news:\u00a0<span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"http:\/\/www.fedaiisf.it\/en\/in-boehringer-scioperi-contro-176-licenziamenti\/\" target=\"_blank\">In Boehringer strike on October 30 against 176 layoffs. The press release of the RSU<\/a><\/span><\/p>\n<p class=\"npStoryTitle npNoBreak\"><a href=\"http:\/\/www.nationalpost.com\/news\/business-wire\/detail.html?b=www.businesswire.com%2Fnews%2Fsyndication%2F20151111005502%2Fen%2FBoehringer-Ingelheim-Invest-11-Billion-Euros-Research\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Boehringer Ingelheim Will Invest 11 Billion Euros in Research and Development in the Next Five Years to Accelerate the Discovery of Next Generation Medical Breakthroughs<\/span><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Boehringer Ingelheim annuncia una nuova strategia di Ricerca &amp; Sviluppo e un piano quinquennale d\u2019investimenti. Nell\u2019arco dei prossimi 5 anni, l\u2019azienda si impegna a investire nel suo nuovo programma di Ricerca &amp; Sviluppo un totale di 11 miliardi di euro, di cui 5 miliardi in preclinica e 1,5 miliardi in collaborazioni con partner esterni. L\u2019azienda &hellip;<\/p>","protected":false},"author":4,"featured_media":5617,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-22774","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/22774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=22774"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/22774\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/5617"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=22774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=22774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=22774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}